DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
The Life, Death, and Dream of a Research Diversity Crusader
“We want to have a nation in which the accidents and circumstances of our birth aren’t determining our fate,” he told a room of reporters a few days later. “And if we’re born with a particular disease or a particular genetic makeup that makes us more vulnerable to something; that that’s not our destiny, that’s not our fate—that we can remake it.”
They were the words Shakir Cannon had been waiting his whole life to hear. For 32 years he had been living with a genetic disorder, sickle cell disease, which predominantly affects African Americans. He managed it the same way people had been doing for decades: He got monthly blood transfusions and took medications for the crippling bouts of pain in his bones and joints. He didn’t have the money for a bone marrow transplant. But he dreamed that one day there’d be an affordable, universal cure—and he was a vocal advocate for research to make that a reality.
Related Content
-
education & researchSickle Cell Disease – Tips for Healthy LivingIt is very important that every person o...
-
people & placesJoshua Field, MD, MSDr. Joshua Field is an Associate Medical...
-
people & placesJeff Glassberg, MDDr. Jeffrey Glassberg obtained his MD an...
-
news & eventsAcetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Ga...Acetylon Pharmaceuticals, Inc., the lead...
-
news & eventsGenetic Treatments for Sickle CellFor decades physicians have known that a...
-
news & eventsSafety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
news & eventsSickle Cell Patient Receives CRISPR Gene TherapyMany human diseases can be traced back t...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.